SNY - Sanofi

NYSE - Nasdaq Real Time Price. Currency in USD
44.88
+0.27 (+0.61%)
As of 10:37AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close44.61
Open45.02
Bid44.90 x 800
Ask44.91 x 2200
Day's Range44.86 - 45.08
52 Week Range37.43 - 46.25
Volume316,610
Avg. Volume1,591,613
Market Cap110.569B
Beta (3Y Monthly)0.56
PE Ratio (TTM)27.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.86 (4.08%)
Ex-Dividend Date2018-05-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • 6 Pharmaceutical Stocks to Buy After the Midterms
    InvestorPlace4 days ago

    6 Pharmaceutical Stocks to Buy After the Midterms

    Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.

  • Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
    Zacks4 days ago

    Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

    Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

  • Investor's Business Daily7 days ago

    Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its Outlook

    Regeneron Pharmaceuticals crushed Wall Street's third-quarter profit views by 66 cents, though sales of eye drug Eylea lagged outside the U.S.

  • Europe: Key Growth Driver for Mylan
    Market Realist5 days ago

    Europe: Key Growth Driver for Mylan

    In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.

  • Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
    Zacks6 days ago

    Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

    Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

  • Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
    Zacks7 days ago

    Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line

    Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.

  • Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript

    REGN earnings call for the period ending September 30, 2018.

  • Teva Pharmaceutical’s Performance in European Markets
    Market Realist7 days ago

    Teva Pharmaceutical’s Performance in European Markets

    In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.

  • Reuters7 days ago

    Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

    The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi (SASY.PA) and Regeneron (REGN.O), the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.

  • Reuters7 days ago

    Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

    The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.

  • Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
    Zacks11 days ago

    Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

    Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

  • Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
    Zacks12 days ago

    Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?

    Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.

  • Benzinga12 days ago

    The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...

  • The Wall Street Journal12 days ago

    [$$] European Corporate Roundup

    Disappointing results from Credit Suisse and Royal Dutch Shell set a slightly negative tone in European markets on another busy day of corporate news.

  • The Wall Street Journal12 days ago

    [$$] Sanofi, Denali Tie Up $1B Deal

    Sanofi and Denali Therapeutics have entered a collaboration agreement valued at up to $1.02 billion to develop molecules to treat neurological and systemic inflammatory diseases.

  • Sanofi (SAN) Q3 Earnings Conference Call Transcript
    Motley Fool13 days ago

    Sanofi (SAN) Q3 Earnings Conference Call Transcript

    SAN earnings call for the period ending September 30, 2018.

  • Sanofi (SNY) Q3 2018 Earnings Conference Call Transcript
    Motley Fool13 days ago

    Sanofi (SNY) Q3 2018 Earnings Conference Call Transcript

    SNY earnings call for the period ending September 30, 2018.

  • Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates
    Zacks13 days ago

    Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates

    Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.

  • Reuters13 days ago

    Vaccines and Genzyme help Sanofi keep promise of return to growth

    Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations. The French drugmaker, hurt by declining sales of its diabetes treatments and a struggle to refill its drug pipeline fast enough in recent years, said it now expected earnings per share to grow by between 4 and 5 percent this year, up from a previous 3-5 percent target range. Investors were keen to see Sanofi deliver on its pledge to achieve growth in the third quarter following a flat first half.

  • Reuters13 days ago

    Vaccines and Genzyme help Sanofi keep promise of return to growth

    Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations. The French drugmaker, hurt by declining sales of its diabetes treatments and a struggle to refill its drug pipeline fast enough in recent years, said it now expected earnings per share to grow by between 4 and 5 percent this year, up from a previous 3-5 percent target range. Investors were keen to see Sanofi deliver on its pledge to achieve growth in the third quarter following a flat first half.

  • Associated Press13 days ago

    Sanofi: 3Q Earnings Snapshot

    On a per-share basis, the Paris-based company said it had profit of $1.06. Earnings, adjusted for non-recurring costs, were $1.07 per share. The results beat Wall Street expectations. The average estimate ...

  • Bloomberg13 days ago

    Sanofi Lifts Forecast as Vaccines, Eczema Drug Provide Fuel

    The low end of the range is 1 percentage point higher than Sanofi’s previous forecast. Sanofi’s third-quarter earnings -- the first gain since the second quarter of last year -- beat analyst estimates. Key InsightsThe results show that a drug Sanofi is relying on as a key driver -- Dupixent, for a severe form of eczema -- is living up to its promise with sales of 225 million euros ($255 million), slightly ahead of analysts’ estimates.The company needs new products because older stalwarts are slumping: Diabetes treatment Lantus plunged 18 percent in the quarter amid fierce competition in the U.S. Sanofi is counting on $16 billion of takeovers, including its purchase of Bioverativ, to help spur growth.Sanofi is also getting a lift from its vaccine business, whose sales are now projected to grow in the mid- to high-single-digit range in the second half, slightly better than previous forecasts, the new finance chief, Jean-Baptiste Chasseloup de Chatillon, told reporters on a call.

  • The Wall Street Journal13 days ago

    [$$] Sanofi Returns to Growth

    SA (SAN.FR) reported a rise in key third-quarter metrics Wednesday, with its bet on higher-value drugs seeming to offset declining revenue from its diabetes division, long afflicted by the loss of exclusivity for former blockbusters. Net sales at the company increased to 9.39 billion euros ($10.67 billion) from EUR9.06 billion the year prior, buoyed by sales of vaccines and by the specialty-care division Sanofi Genzyme, which grew 36% on year. Business net income--an important, adjusted metric for the company that excludes amortization, impairments, restructuring costs and other values--increased to EUR2.30 billion from EUR2.14 billion the year before, Sanofi said.

  • Sanofi: Analysts’ Recommendations on October 30
    Market Realist14 days ago

    Sanofi: Analysts’ Recommendations on October 30

    Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date.

  • European shares bounce as investors find comfort in earnings
    Reuters Videos13 days ago

    European shares bounce as investors find comfort in earnings

    European shares rallied on Wednesday as a tumultuous October drew to a close and strong results from L’Oreal, Sanofi and banks Standard Chartered and Santander soothed investors’ nerves. Laura Frykberg reports.